Investment Thesis
Compass Therapeutics is a pre-revenue biotech company burning substantial cash with negative operating cash flow of -$49.1M annually against minimal cash reserves of $30.6M, indicating a critical funding timeline. The company is unable to sustain operations without external financing, and at current burn rates faces less than 8 months of runway without additional capital.
Strengths
- Strong balance sheet with zero long-term debt and $196.8M stockholders equity provides capital structure flexibility
- Excellent liquidity position with 15.02x current ratio demonstrates ability to meet short-term obligations
- Low financial leverage (0.0x debt-to-equity) reduces insolvency risk during drug development phase
Risks
- Zero revenue with 100% YoY revenue decline indicates no commercial product traction or FDA approvals
- Severe cash burn of -$49.1M in operating cash flow against only $30.6M in liquid reserves creates immediate solvency risk
- Negative ROE (-33.8%) and ROA (-30.3%) demonstrate the company is destroying shareholder value at an accelerating rate
- Net losses of -$66.5M indicate R&D spending is not yielding revenue-generating outcomes
- Pre-clinical/clinical stage biotech with no path to profitability visible in financial data
Key Metrics to Watch
- Cash burn rate and months of runway remaining before funding requirement
- Clinical trial progression and FDA milestone announcements
- Operating cash flow trajectory and capital raise announcements
Financial Metrics
Revenue
0.0
Net Income
-66.5M
EPS (Diluted)
$0.00
Free Cash Flow
-49.2M
Total Assets
219.6M
Cash
30.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-33.8%
ROA
-30.3%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
15.02x
Quick Ratio
15.02x
Debt/Equity
0.00x
Debt/Assets
10.4%
Interest Coverage
N/A
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-22T14:12:11.125027 |
Data as of: 2025-12-31 |
Powered by Claude AI